JP2010533727A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533727A5
JP2010533727A5 JP2010517123A JP2010517123A JP2010533727A5 JP 2010533727 A5 JP2010533727 A5 JP 2010533727A5 JP 2010517123 A JP2010517123 A JP 2010517123A JP 2010517123 A JP2010517123 A JP 2010517123A JP 2010533727 A5 JP2010533727 A5 JP 2010533727A5
Authority
JP
Japan
Prior art keywords
cycloalkyl
aryl
alkyl
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010517123A
Other languages
English (en)
Japanese (ja)
Other versions
JP5301539B2 (ja
JP2010533727A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/070103 external-priority patent/WO2009012277A1/en
Publication of JP2010533727A publication Critical patent/JP2010533727A/ja
Publication of JP2010533727A5 publication Critical patent/JP2010533727A5/ja
Application granted granted Critical
Publication of JP5301539B2 publication Critical patent/JP5301539B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010517123A 2007-07-17 2008-07-16 Gpr119gタンパク質共役受容体の調節方法および選択された化合物 Expired - Fee Related JP5301539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95016207P 2007-07-17 2007-07-17
US60/950,162 2007-07-17
PCT/US2008/070103 WO2009012277A1 (en) 2007-07-17 2008-07-16 Method for modulating gpr119 g protein-coupled receptor and selected compounds

Publications (3)

Publication Number Publication Date
JP2010533727A JP2010533727A (ja) 2010-10-28
JP2010533727A5 true JP2010533727A5 (enExample) 2011-03-24
JP5301539B2 JP5301539B2 (ja) 2013-09-25

Family

ID=39864683

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010517123A Expired - Fee Related JP5301539B2 (ja) 2007-07-17 2008-07-16 Gpr119gタンパク質共役受容体の調節方法および選択された化合物
JP2010517122A Expired - Fee Related JP5318867B2 (ja) 2007-07-17 2008-07-16 ピリドンgpr119gタンパク質共役受容体アゴニスト
JP2013144778A Withdrawn JP2013237680A (ja) 2007-07-17 2013-07-10 ピリドンgpr119gタンパク質共役受容体アゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010517122A Expired - Fee Related JP5318867B2 (ja) 2007-07-17 2008-07-16 ピリドンgpr119gタンパク質共役受容体アゴニスト
JP2013144778A Withdrawn JP2013237680A (ja) 2007-07-17 2013-07-10 ピリドンgpr119gタンパク質共役受容体アゴニスト

Country Status (26)

Country Link
US (6) US7928230B2 (enExample)
EP (2) EP2170864B1 (enExample)
JP (3) JP5301539B2 (enExample)
KR (2) KR20100051814A (enExample)
CN (3) CN103550218A (enExample)
AR (2) AR067569A1 (enExample)
AT (2) ATE524460T1 (enExample)
AU (2) AU2008276057B2 (enExample)
BR (2) BRPI0814428A2 (enExample)
CA (2) CA2693439A1 (enExample)
CL (2) CL2008002110A1 (enExample)
CO (1) CO6160315A2 (enExample)
CY (2) CY1112151T1 (enExample)
DK (2) DK2173737T3 (enExample)
EA (2) EA018709B1 (enExample)
ES (2) ES2371515T3 (enExample)
HR (2) HRP20120221T1 (enExample)
IL (1) IL228120A0 (enExample)
NZ (2) NZ582661A (enExample)
PE (2) PE20090888A1 (enExample)
PL (2) PL2173737T3 (enExample)
PT (2) PT2173737E (enExample)
SI (2) SI2173737T1 (enExample)
TW (2) TW200904439A (enExample)
WO (2) WO2009012277A1 (enExample)
ZA (2) ZA201000151B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006059778A1 (ja) * 2004-12-01 2008-06-05 萬有製薬株式会社 置換ピリドン誘導体
JP2010526145A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー [6,6]および[6,7]−二環式gpr119gタンパク質結合受容体アゴニスト
CA2693439A1 (en) * 2007-07-17 2009-01-22 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010009208A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
EP2408780A2 (en) * 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
JP5467151B2 (ja) 2009-06-24 2014-04-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2556069B1 (en) 2010-04-08 2015-04-01 Bristol-Myers Squibb Company 4-(1-(pyrimidin-2-yl)piperidin-4-yloxy)pyridin-2-one compounds as gpr119 modulators
CN102971311B (zh) 2010-05-06 2015-07-08 百时美施贵宝公司 作为gpr119调节剂的二环杂芳基化合物
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8785463B2 (en) 2010-10-08 2014-07-22 Cadila Healthcare Limited GPR 119 agonists
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
PL2648516T3 (pl) 2010-12-06 2019-04-30 Aclaris Therapeutics Inc Podstawione związki pirydynono-pirydynylowe
US8822471B2 (en) * 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
SG11201503716RA (en) * 2012-11-13 2015-06-29 Nissan Chemical Ind Ltd 2-pyridone compound
CN102993088A (zh) * 2012-12-31 2013-03-27 东华大学 一种4-羟基-2-吡啶酮的制备方法
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
HRP20210813T1 (hr) 2013-06-07 2021-06-25 Aclaris Therapeutics, Inc. Piridinonpiridinilni spojevi supstituirani s metil/fluorpiridinilmetoksi i piridinonpiridinilni spojevi supstituirani s fluorpirimidinilmetoksi
EP3010893B1 (de) 2013-06-20 2019-10-02 Bayer CropScience Aktiengesellschaft Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
WO2014202505A1 (de) 2013-06-20 2014-12-24 Bayer Cropscience Ag Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
CN105517995B (zh) 2013-07-08 2018-10-02 拜耳作物科学股份公司 作为农药的六元c-n键合的芳基硫化物和芳基硫氧化物衍生物
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016130652A1 (en) 2015-02-10 2016-08-18 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) * 2015-03-25 2019-09-18 公益財団法人相模中央化学研究所 一置換(フルオロアルキル)エチレン類及びその製造方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CA3172088A1 (en) 2020-03-27 2021-09-30 Walter Smith Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) * 2022-08-15 2022-12-23 广西中医药大学 4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
TR200100149T2 (tr) 1998-07-06 2001-10-22 Bristol-Myers Squibb Company Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
EP1058549A4 (en) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
AU2001275857A1 (en) 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
JP3438186B2 (ja) 2000-12-01 2003-08-18 山之内製薬株式会社 糖尿病治療剤スクリーニング方法
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CN100486576C (zh) * 2002-02-14 2009-05-13 法玛西雅公司 作为p38map激酶调节剂的取代吡啶酮类
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
PL378295A1 (pl) 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7003597B2 (en) * 2003-07-09 2006-02-21 International Business Machines Corporation Dynamic reallocation of data stored in buffers based on packet size
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN100509798C (zh) * 2003-07-11 2009-07-08 艾尼纳制药公司 作为新陈代谢调节剂的三取代芳基和杂芳基衍生物以及预防和治疗与其相关之病症
RS20060018A (sr) * 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
US20070088163A1 (en) 2003-09-12 2007-04-19 Kemia, Inc. Modulators of calcitonin and amylin activity
CA2558272C (en) * 2004-03-05 2011-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
DK2060266T3 (da) 2004-03-17 2011-11-14 7Tm Pharma As Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb
EP1756096B1 (en) 2004-05-03 2009-08-12 F.Hoffmann-La Roche Ag Indolyl derivatives as liver-x-receptor modulators
DK1756084T3 (da) 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Gタンパク質結合受容体作動薬
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
CA2612187C (en) 2005-06-23 2013-05-07 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007003960A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
PE20090213A1 (es) * 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
JP2010526145A (ja) * 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー [6,6]および[6,7]−二環式gpr119gタンパク質結合受容体アゴニスト
CA2693439A1 (en) 2007-07-17 2009-01-22 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists

Similar Documents

Publication Publication Date Title
JP2010533727A5 (enExample)
JP2010526146A5 (enExample)
JP2011513305A5 (enExample)
JP2008510828A5 (enExample)
JP2011520792A5 (enExample)
JP2011515398A5 (enExample)
JP2012510502A5 (enExample)
JP2011504935A5 (enExample)
EP2592070A3 (en) Tetrazole-substituted arylamides
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
JP2011519374A5 (enExample)
JP2018509418A5 (enExample)
JP2011504903A5 (enExample)
JP2005053931A5 (enExample)
JP2010533726A5 (enExample)
JP2011518163A5 (enExample)
JP2013544276A5 (enExample)
JP2012505234A5 (enExample)
JP2020500182A5 (enExample)
JP2011513410A5 (enExample)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
SI20876B (sl) Derivati propanojske kisline, ki inhibirajo vezavo integrinov na njihove receptorje
JP2011504504A5 (enExample)
JP2017508795A5 (enExample)
JP2013506674A5 (enExample)